Darusentan

DB04883InvestigationalSmall molecule

Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

Chemical structure of Darusentan
Mechanism
Curator reviewed
Primary indication
For the treatment of congestive heart failure and hypertension.Curator reviewed
Formula / weight
C22H22N2O6 · 410.4199 g/mol (avg)
Code names
LU-135252

Resolves to

Structure
InChIKeyFEJVSJIALLTFRP-LJQANCHMSA-NSMILESCOC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
13+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Darusentan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account